Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07218432

A Study of the TheraBionic P1 Device in Breast Cancer

The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Breast Cancer Stage I Breast Cancer Stage II Breast Cancer Stage IIIA Breast Diseases Breast Neoplasms HER2-negative Breast Cancer Hormone Receptor Positive Tumor Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

22 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Karmanos Cancer Institute at McLaren Clarkston, Clarkston, Michigan, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must have histologically proven invasive breast cancer that is HR (hormone receptor) positive and HER2 (Human Epidermal Growth Factor Receptor 2) negative according to the 2010 American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (ER and/or PR (progesterone receptor) >1% and HER2 negative by immunohistochemistry [IHC] and/or fluorescent in situ hybridization [FISH]).
  • Participant must have early-stage operable disease (stage I-II or III who have planned upfront surgery) and agree to definitive upfront surgery.
  • Participant must be available for at least two weeks of TheraBionic treatment prior to scheduled resection
  • Participant must have archival tissue available.
  • Participant must be a woman aged 22 years or older
  • Participant must be able to understand a written informed consent document and be willing to sign it
  • Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • It is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, women of child-bearing potential must agree to avoid becoming pregnant starting at initiation of treatment up until at least 30 days after the last TheraBionic P1 session

Exclusion criteria

  • Participants that are receiving or will receive neoadjuvant chemotherapy or neoadjuvant hormonal therapy
  • Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints
  • Participants that are taking any other investigational drugs
  • Participants that are pregnant or breastfeeding due to the unknown but potential risk for adverse events. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued
  • Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae).
  • Participants receiving calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, ascorbic acid/vitamin C, etc.) unless their medical treatment is discontinued at least one day prior to treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study.
  • Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device
  • Participants with a known severe (e.g., anaphylactic) allergy to nickel.

Treatment and study plan

TheraBionic P1 Device

Device

Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day and in the evening prior to surgical resection of early stage breast cancer.

Primary outcomes

  1. Pathological Response to Treatment

    Time frame: At time of surgery (after approximately 2 weeks of treatment and tumor resection)

    Proportion of responders based on residual cancer cells in a resection specimen will be quantified. The response rate will be estimated as the proportion of patients who respond to treatment relative to all patients. The corresponding two-sided 95% confidence interval (CI) will be calculated using Clopper and Pearson's method

Secondary outcomes

  1. Changes in microRNA expression in tumor tissue

    Time frame: Baseline to post-surgical resection

    Changes in microRNA expression in tumor tissue pre- and post-treatment will be calculated as the difference between pre- and post-treatment expression values with two-sided 95% CI estimated using a standard t-distribution-based formula for paired differences.

  2. Changes in Ki-67 expression in tumor tissue

    Time frame: Baseline to post-surgical resection

    Changes in Ki-67 expression in tumor tissue pre- and post-treatment will be calculated as the difference between pre- and post-treatment expression values with two-sided 95% CI estimated using a standard t-distribution-based formula for paired differences.

  3. Changes in tumor apoptosis marker Cleaved caspase-3 (CC3) in tumor tissue

    Time frame: Baseline to post-surgical resection

    Changes in CC3 expression in tumor tissue pre- and post-treatment will be calculated as the difference between pre- and post-treatment expression values with two-sided 95% CI estimated using a standard t-distribution-based formula for paired differences.

  4. Changes in cell cycle arrest marker p27 in tumor tissue

    Time frame: Baseline to post-surgical resection

    Changes in p27 expression in tumor tissue pre- and post-treatment will be calculated as the difference between pre- and post-treatment expression values with two-sided 95% CI estimated using a standard t-distribution-based formula for paired differences.

  5. Overall survival (OS)

    Time frame: Up to 5 years post-surgery

    OS will be graphically summarized using Kaplan-Meier (KM) curves, with corresponding medians and two-sided 95% CIs computed using KM estimates. Additionally, OS rates at every six months post-treatment will be estimated using the KM estimated, with two-sided 95% CIs provided for each time point.

  6. Progression Free Survival (PFS)

    Time frame: Up to 5 years post-surgery

    PFS will be graphically summarized using Kaplan-Meier (KM) curves, with corresponding medians and two-sided 95% CIs computed using KM estimates. Additionally, PFS rates at every six months post-treatment will be estimated using the KM estimated, with two-sided 95% CIs provided for each time point.

Other outcomes

  1. Positron Emission Tomography with 3'-Deoxy-3'-18F-Fluorothymidine (PET-FLT) association of response to treatment

    Time frame: From Screening to after 7 days of treatment with the TheraBionic Device.

    Changes in the SUV max as measured by FLT-PET prior to treatment compared to after treatment and before resection. SUV (standard uptake value) max values will be log-transformed and descriptively summarized using the mean, standard deviation, and two-sided 95% CI. Changes in SUV max pre- and post-treatment will be calculated as the difference between the pre- and post-treatment values with two-sided 95% CI estimated using a standard t-distribution-based formula for paired differences. The association between changes in SUV max and response will be explored using logistic regression analysis. Optional study for the first 5 participants.

Study contacts

Contact information is provided by the study sponsor or research team.

Lubina Arjyal, M.D.

CONTACT

[email protected]

1-800-karmanos

Sponsors and collaborators

Lead sponsor

Barbara Ann Karmanos Cancer Institute

Other

Registry information

Official study title

A Window of Opportunity Pilot Study: TheraBionic P1 Device for Patients With Resectable Early-stage Breast Cancer in a Neoadjuvant Setting

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Oct 20, 2025
Registry last updated
Apr 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.